Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Fiche publication
Date publication
avril 2016
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Dr RIOS Maria
Tous les auteurs :
Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M
Lien Pubmed
Résumé
Imatinib has dramatically improved the prognosis of advanced gastrointestinal stromal tumours (GISTs). Clinical trial data showed that patients with trough imatinib plasma concentrations (Cmin) below 1100 ng/ml (quartile 1) had shorter time to progression, but no threshold has been defined. The main objective of this study was to investigate in advanced GIST whether a Cmin threshold value associated with a longer progression-free survival (PFS) could be specified. This would be the first step leading to therapeutic drug monitoring of imatinib in GIST.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, metabolism, Disease Progression, Drug Monitoring, Female, Gastrointestinal Neoplasms, drug therapy, Gastrointestinal Stromal Tumors, blood, Humans, Imatinib Mesylate, metabolism, Intestine, Small, chemistry, Kaplan-Meier Estimate, Male, Middle Aged, Prospective Studies, Stomach, chemistry, Treatment Outcome
Référence
Eur. J. Cancer. 2016 Apr;57:31-8